Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Research & Development (2016 - 2025)

Aytu Biopharma has reported Research & Development over the past 12 years, most recently at $216000.0 for Q2 2025.

  • Quarterly Research & Development fell 79.27% to $216000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $378000.0 through Dec 2025, down 85.47% year-over-year, with the annual reading at $1.3 million for FY2025, 52.11% down from the prior year.
  • Research & Development was $216000.0 for Q2 2025 at Aytu Biopharma, up from $162000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $4.8 million in Q2 2021 and troughed at $162000.0 in Q1 2025.
  • The 5-year median for Research & Development is $856000.0 (2023), against an average of $1.5 million.
  • Year-over-year, Research & Development soared 1464.69% in 2021 and then plummeted 85.71% in 2023.
  • A 5-year view of Research & Development shows it stood at $4.5 million in 2021, then tumbled by 61.79% to $1.7 million in 2022, then crashed by 69.53% to $521000.0 in 2023, then grew by 0.19% to $522000.0 in 2024, then plummeted by 58.62% to $216000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Research & Development are $216000.0 (Q2 2025), $162000.0 (Q1 2025), and $522000.0 (Q4 2024).